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Mouse hybridomas secreting antibodies to human insulin-like growth factor I (IGF I) were produced by 
fusion of spleen cells of hyperimmunised mice with FO mouse-myeloma cells. Eight clones producing anti- 
bodies against human IGF I have been isolated, two of which have been characterised. One was used in 
a radioimmunoassay, the other for immunopurification of IGF. 
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1. INTRODUCTION 
The insulin-like growth factors I and II (IGF I 
and II) are polypeptides which have been isolated 
from human serum [l]. Their amino acid se- 
quences are homologous to the one of proinsulin 
[2,3]. IGF I and II act in vitro as growth factors on 
fibroblasts, chondrocytes and osteocytes [4]. In 
vivo IGF I induces growth in hypophysectomised 
rats and widening of the epiphyseal cartilage [4]. 
The concentration of IGF I and to a lesser extent 
that of IGF II in human serum have been shown to 
be under control of growth hormone [5]. Pygmies 
are deficient of IGF I in serum, whereas their levels 
of IGF II are within the normal range [6]. IGF I 
thus qualifies as somatomedin, whereas the 
physiological role for IGF II is less clear. Here, we 
describe the production of monoclonal antibodies 
against IGF I by the hybridoma technique [7]. An 
unlimited amount of such antibodies would allow 
the preparation of IGF from serum by immunoad- 
sorption and the determination of serum levels of 
IGF I in patients with growth disorders on a wider 
scale. 
2. MATERIALS AND METHODS 
* To whom correspondence should be addressed 
Abbreviation: RIA, radioimmunoassay 
Parts of this work have been presented at the 14th 
annual meeting of the Swiss Societies for Experimental 
Biology, Interlaken, l-2 April, 1982 
Human IGF I was prepared as in [l]. It was con- 
jugated to tetanus toxoid (Schweizerisches Serum- 
und Impfinstitut, Bern) using 1-ethyl-3-(3-di- 
methylaminopropyl)-carbodiimide . HCl (Serva, 
Heidelberg) as a coupling agent [8]. The molar 
ratio of peptide to carrier was 7: 1. Two sub- 
cutaneous injections of 20,ug coupled antigen 
dissolved in complete Freund’s adjuvant were 
given to 5 adult BALB/c mice in 3 week intervals. 
Three out of these 5 mice were injected in- 
traperitoneally with 3 daily doses of 2Opg con- 
jugated IGF I in saline. The next day, the spleens 
were used for cell fusion with FO myeloma cells 
[9]. Colonies were detectable in 568 of 1500 micro- 
plate wells (Dynatech, Sussex). Cultures producing 
antibodies to IGF I were cloned twice by limited 
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dilution. For the production of larger amounts of 
antibodies, cells were injected intraperitoneally in- 
to BALB/c mice (5 x lo7 cells/mouse). A few days 
later serum and ascites fluid were collected. A 
solid-phase antibody-binding assay (see below) 
utilising subclass specific rabbit anti-mouse anti- 
bodies (Nordic, Tilburg) was employed to deter- 
mine the IgG subclasses. 
The chloramine T method was used for iodina- 
tion (lz51, EidgenGssisches Institut fiir Reaktor- 
forschung, Wiirenlingen) of IGF I [5] and protein 
A (2.5&i/pg, Pharmacia, Uppsala) [lo]. Sera of 
immunised animals and culture supernatants were 
tested for antibodies at several dilutions in a solid- 
phase antibody-binding assay [ 1 l] using polyvinyl 
chloride microtiter plates (Dynatech M 25) coated 
with IGF I (2pg/ml). 1251-labelled protein A 
(50000 cpm/well) was added after rabbit anti- 
mouse antiserum (1: 60, Nordic RAM/IgG 
(H + L)) used as a link to anti-IGF I. Supernatants 
giving a positive reaction were further tested by a 
radioimmunoassay (RIA) using polyethyleneglycol 
6000 (Fluka, Buchs) to separate free and bound 
‘*‘I-1GF [12]. Levels of IGF I in sera of patients 
and recoveries of IGF I and II after immunopurifi- 
cation have been determined by a RIA using con- 
ventional antiserum to IGF I and II, respectively 
[51. 
The proteins of 0.4 ml ascites fluid were coupled 
to 2 ml of CNBr-activated Sepharose (Pharmacia). 
Serum (15 ml) was gel-filtered on Sephadex G-75 in 
0.5 M acetic acid to dissociate IGF from its carrier 
protein [5], lyophilised, dissolved in 300~1 5 mM 
HCl and applied to the column in 3.5 ml 
phosphate-buffered saline (10 mM phosphate buf- 
fer, pH 7.4; 0.15 M NaCl). The column was wash- 
ed with 20ml 0.5 M NaCl, 25 mM Tris .HCl 
(pH 7.5), 0.2% Triton X-100 and with 1Oml 5 mM 
phosphate buffer, (pH 7.4). Elution was perform- 
ed with 0.5M acetic acid. Protein determinations 
were done according to [ 131 using Coomassie blue. 
Biological activity was determined in the fat cell 
assay [14]. The affinity purified IGF was 
characterised by reversed phase high-performance 
liquid chromatography [15]. A 4.6 x 250 mm 
Chromosorb LC-7 column (Brownlee Labs., Santa 
Clara, CA 95050), flow rate 1 ml/min at room 
temperature, was used. Buffer A was 1OmM 
NaClO, in 19mM H3P04, buffer B 60% (v/v) 
acetonitrile in A. 
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3. RESULTS AND DISCUSSION 
Eight of 568 hybrids (1.4% yield) produced anti- 
bodies of the IgG, type that are directed against 
IGF I as determined in the solid-phase anti- 
body-binding assay. All showed a stable in vitro 
production of antibodies over 3 months and were 
successfully grown intraperitoneally in mice. 
Five of the 8 antibody preparations showed a 
significant binding of 1251-IGF I as determined by 
the RIA. The one with the highest affinity for IGF 
I (41/81, -lo9 M-l) was used for determination 
of IGF I levels in human sera. Cell supernatant or 
ascites fluid 41/81 were used at a final dilution of 
1:200 or 1:20000, respectively, at which they 
bound 50% of ‘*‘I-IGF I. Fig. 1 shows the 
displacement of 1251-IGF I by unlabelled IGF I. 
Half-maximal displacement was achieved by 
1.3-l .4 ng IGF/0.2 ml. The lowest concentration 
detectable was 0.2 ng IGF/0.2 ml. IGF II showed a 
crossreactivity of 3%, whereas human insulin did 
not displace ‘*‘I-IGF I even at 50pg/0.2ml. A 
linear relationship was observed between the 
amount of serum and the detectable IGF I (fig. 2). 
Sera of patients with abnormal IGF I levels and 
two serum pools of subjects with normal levels 
were analysed by RIA using both the monoclonal 
antibody 41/81 and the conventional antiserum. 
The two methods gave similar results (table l), 
showing that both types of antibody are directed 
against the same antigen. Within-assay and be- 
tween-assay standard deviations were 6% (n = 10) 
and 11% (n = 7), respectively. Sera from several 
species were tested for crossreactivity against IGF 
I tracer. The approximate relative potencies of 
Unlabelled IGF, ngltube 
Fig. 1. Competitive inhibition of binding of ‘2SI-IGF I to 
cell supernatant 41/81 by unlabelled IGF I (0) and IGF 
II (0). All points are the mean of duplicates. 
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Table 1 
Determination of serum levels of IGF I with conven- 
tional antiserum and cell supernatant 41181 
Serum 
source 
Normals 
Pool RIA with RIA with cell 
conventional supernatant 
antiserum 41/81 
(ngiml) (ngiml) 
(1) 160 175 
(2) 145 145 
Acromegalics (3) 580 560 
(4) 700 850 
(5) 785 930 
(6) 1060 1060 
Patients with (7) <40 c40 
IGF deficiency (8) <40 <40 
(9) <40 <40 
Results are the mean of duplicates at two different dilu- 
tions. Two pools of serum from subjects with normal 
IGF I levels (1,2), sera from 4 acromegalic patients 
(3-6), from two patients with extrapancreatic tumor 
hypoglycemia (7,8) and from one suffering from 
Leprechaunism (9) were tested 
IO 20 30 40 30 60 
Serum, pl 
Fig. 2. Correlation of amounts of stripped serum with 
estimation of IGF-I by RIA using antibody 41181. 
guinea pig, rabbit, human, rat and mouse sera 
were 7:4: 1: <O.Ol: <O.Ol. 
The use of a monoclonal antibody in a RIA for 
somatomedin-CYIGF I was reported in [16]. This 
antibody seems to have a higher affinity, but a 
lower specificity as judged by crossreaction with 
IGF II than the antibody 41/81. The limited avail- 
ability of pure IGF I has so far prevented the large- 
scale production of conventional antiserum needed 
for radioimmunoassays on a wider scale. With the 
hybrid 41/81 we have now a theoretically unlimited 
source of antibodies to study IGF-I levels in sera of 
patients with growth disorders. The low crossreac- 
tivity of antibody 41/81 with IGF-II should prove 
of special value. 
A monoclonal antibody with a lower affinity for 
IGF I (43/81, -10’ M-‘) was used for im- 
munopurification of IGF. Coupled to Sepharose, 
the 20mg proteins of 400~1 ascites fluid bound 
96% of the IGF I and 97% of the IGF II in the 
crude IGF-preparation derived from 15 ml serum 
(table 2). Of the total proteins 99% were detected 
in the neutral flow trough. Bound IGF I and II 
could be eluted with 0.5 M acetic acid with a 
recovery of 64% and 80070, respectively. A 200-fold 
purification was obtained. However, the affinity 
column does not discriminate between IGF I and 
II, using either antibody 43181 or 41/81 (not 
shown). Analysis by HPLC of affinity purified 
IGF is illustrated in fig. 3. The elution points for 
IGF I and II were 65% buffer B, corresponding to 
the positions of conventionally purified IGF I and 
II. At 67% buffer B, a third component active in 
the RIA for IGF II was detected which has not 
been further characterised. The large peak at 90% 
buffer B is due to an impurity of non-protein 
origin as judged by Coomassie-blue protein deter- 
mination and by the absorption spectra in the 
Fraction 
Table 2 
Immunopurification of IGF using antibody 43181 
IGF I IGF II Protein Purity of 
IGF 
Biological 
activity 
Applied to column 1.57/g 8.1 fig 14.3 mg 0.068% 5.2 mU 
Neutral flowthrough o.o7/cg 0.26pg 14.2mg - <0.22 mU 
Acidic eluate 0.96pg 6.3 rg 56 pg 13% 4.0 mU 
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Fig. 3. High-performance liquid chromatography of IGF 
(1.4,ug IGF I and 6pg IGF II) purified by immunoad- 
sorption. IGF I (u) and II (0) concentration was 
measured by RIA. 
ultraviolet range. Although it was not possible to 
separate IGF I from IGF II by immunopurification 
and high-performance liquid chromatography, the 
purity of IGF (IGF I and II combined) obtained by 
this procedure was found to be 0.75ng RIA 
equiv./l .O ng protein as determined by absorption 
at 220 nm. This three-step purification procedure 
for IGF with 75% purity of the end product and an 
overall yield of 60% represents an attractive alter- 
native to the method in [l]. 
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